Omega Therapeutics shares surge on obesity collaboration with Novo NordiskProactive Investors • 01/04/24
Ozempic parent Novo Nordisk enters collaboration agreements with Omega and Cellarity on new treatments for obesity managementMarket Watch • 01/04/24
Novo Nordisk faces number of overlooked trends including competition for Wegovy, warns investment bankProactive Investors • 01/03/24
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss IndustryThe Motley Fool • 12/21/23
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.The Motley Fool • 12/21/23
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?Market Watch • 12/20/23